Lab
Elitemed Laboratories, LLC
Elitemed Laboratories, LLC was paid $2.70M by Medicaid between Jun 2018 and Jun 2024, across 85 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 56% of everything it billed.
33Billing provider infoELITEMED LABORATORIES, LLC
ADDISON, TX 75001
ADDISON, TX 75001
33aNPI1730585456assigned 11/06/2014
33bProvider typeClinical Medical Laboratory
28Total paid$2.70M
24GClaims87,798
24DCodes billed85
24AFirst – last monthJun 2018 – Jun 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Texas
Rank by total paid#36 of 436
Median peer was paid$17K
This provider vs. median156×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,245 | $107K | |
| 2019 | 259 | $6K | |
| 2021 | 404 | $12K | |
| 2022 | 27,839 | $973K | |
| 2023 | 42,570 | $1.56M | |
| 2024incomplete | 8,481 | $34K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 56% | 21,543 | 8,363 | $1.50M |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 17% | 21,225 | 8,364 | $455K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 16% | 18,659 | 8,065 | $425K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | 5.2% | 4,468 | 3,563 | $141K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,309 | 424 | $22K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 653 | 226 | $15K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 441 | 241 | $7K |
| 83992 | <1% | 381 | 340 | $6K | |
| 80360 | <1% | 382 | 341 | $5K | |
| 80353 | <1% | 381 | 340 | $5K | |
| 80356 | <1% | 379 | 338 | $5K | |
| 80324 | <1% | 380 | 340 | $5K |
73 more codes
| 80359 | <1% | 380 | $5K | |
| 80372 | <1% | 379 | $5K | |
| 80373 | <1% | 379 | $5K | |
| 80361 | <1% | 379 | $5K | |
| 80364 | <1% | 375 | $5K | |
| 80357 | <1% | 357 | $5K | |
| 80358 | <1% | 353 | $5K | |
| 80368 | <1% | 330 | $5K | |
| 80366 | <1% | 311 | $4K | |
| 80355 | <1% | 311 | $4K | |
| 80348 | <1% | 302 | $4K | |
| 80354 | <1% | 301 | $4K | |
| 80347 | <1% | 258 | $4K | |
| 80370 | <1% | 243 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 68 | $3K |
| 80061 | Lipid panel | <1% | 956 | $3K |
| 80349 | <1% | 171 | $3K | |
| 87428 | <1% | 52 | $2K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 715 | $2K |
| 80337 | <1% | 152 | $2K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 954 | $2K |
| 80053 | Comprehensive metabolic panel | <1% | 1,309 | $2K |
| 80323 | <1% | 142 | $2K | |
| 80299 | <1% | 114 | $2K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,421 | $2K |
| 80369 | <1% | 108 | $2K | |
| 80346 | <1% | 114 | $1K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 797 | $1K |
| 80367 | <1% | 70 | $987.24 | |
| 83690 | <1% | 537 | $963.78 | |
| 83735 | <1% | 605 | $960.92 | |
| 82150 | <1% | 530 | $894.89 | |
| 83615 | <1% | 527 | $834.03 | |
| 84100 | <1% | 542 | $670.67 | |
| 80365 | <1% | 44 | $631.96 | |
| 82248 | <1% | 451 | $613.65 | |
| 82977 | <1% | 506 | $609.58 | |
| 80164 | <1% | 170 | $518.91 | |
| 86480 | <1% | 13 | $411.62 | |
| 82607 | <1% | 135 | $377.18 | |
| 82746 | <1% | 92 | $335.65 | |
| 84439 | <1% | 171 | $300.83 | |
| 80362 | <1% | 349 | $256.20 | |
| 84481 | <1% | 44 | $107.44 | |
| 80178 | <1% | 53 | $100.13 | |
| 84466 | <1% | 13 | $94.29 | |
| 84153 | <1% | 56 | $88.33 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 30 | $82.96 |
| 36415 | Collection of venous blood by venipuncture | <1% | 78 | $58.68 |
| 83540 | <1% | 32 | $47.85 | |
| 81001 | <1% | 79 | $22.94 | |
| 82985 | <1% | 47 | $14.64 | |
| 82575 | <1% | 56 | $8.26 | |
| 84460 | <1% | 54 | $4.62 | |
| 84450 | <1% | 54 | $4.52 | |
| 84075 | <1% | 54 | $4.52 | |
| 82310 | <1% | 53 | $4.50 | |
| 84520 | <1% | 37 | $4.39 | |
| 82247 | <1% | 54 | $4.38 | |
| 82040 | <1% | 54 | $4.32 | |
| 82950 | <1% | 44 | $4.14 | |
| 81003 | <1% | 13 | $3.78 | |
| 82565 | <1% | 55 | $2.24 | |
| 81321 | 0% | 15 | $0.00 | |
| 81404 | 0% | 15 | $0.00 | |
| 81317 | 0% | 15 | $0.00 | |
| 81405 | 0% | 15 | $0.00 | |
| 81408 | 0% | 15 | $0.00 | |
| 81163 | 0% | 15 | $0.00 | |
| 81406 | 0% | 31 | $0.00 | |
| 81201 | 0% | 15 | $0.00 | |
| 81295 | 0% | 15 | $0.00 | |
| 83550 | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialCARR, DAVID (AUTHORIZED OFFICIAL)
| Provider | Location | Paid |
|---|---|---|
| 55 Sandalwood Enterprises INC | Bronx, NY | $1.69M |
| City Testing Centers LLC | New York, NY | $353K |
| Carr Chiropractic and Wellness, LLC | Boyertown, PA | $28K |
| 51 Sandalwood Enterprises INC | Riverhead, NY | $25K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.